This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SCH 900274, ORG-5222, asenapine, Sycrest (EU)
Description: Asenapine, an atypical antipsychotic, is a serotonin, dopamine, and noradrenaline antagonist with a high affinity for a number of receptors for these neurotransmitters, including dopamine (D1, D2L, D3, D4), alpha adrenergic (e.g. alpha2a), and serotonin receptors (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7).
Revenue splits for this drug are BioMedTracker estimates.
Pfizer and Organon (Akzo Nobel)
Pfizer and Organon, the human pharmaceutical business unit of Akzo Nobel, announced on October 2003 that they have entered into a global agreement for the exclusive worldwide development and commercialization of Organon's asenapine, a potential new psychotropic medication for the treatment of a variety of disorders. Under terms of the agreement the companies will collaborate on the clinical development and manufacturing of asenapine, and co-promote the product in the United States, European Union, Japan and other markets. Pfizer will make an initial payment of U.S. dollar 100 million and up to U.S. dollar 270 million in milestone payments contingent upon regulatory approvals and launch of asenapine in the United States, Europe and Japan as well as attainment of certain agreed-upon sales levels. Further terms of the agreement were not disclosed.
In November 2006, Organon...See full deal structure in Biomedtracker
Partners: H. Lundbeck A/S Merck & Co., Inc.
Additional information available to subscribers only: